In a surprising development, however, Shaftel et al. have demonstrated in a mouse model of AD that long-term IL-1β overexpression leads to a reduction in amyloid pathology.

Using the mutant myoglobin, we screened for inhibitors of polyglutamine-mediated protein aggregation and evaluated candidate molecules in cellular and transgenic mouse models of Huntington disease.